Clinical Trial Risk Tool featured in Clinical Leader

· Thomas Wood
Clinical Trial Risk Tool featured in Clinical Leader

The Clinical Trial Risk Tool has been featured in a guest column by Thomas Wood, director of Fast Data Science, in Clinical Leader, titled A Tool To Tackle The Risk Of Uninformative Trials, in cooperation with Abby Proch, Executive Editor at Clinical Leader.

In this article, Thomas Wood discusses the issue of uninformative clinical trials in pharmaceutical research. Uninformative trials fail to provide meaningful results, either because they don’t address key questions or are poorly designed. These trials waste resources, expose participants to unnecessary risks, and hinder progress in medical knowledge.

Wood uses the definition of “uninformative trials” from Zarin et al (2019)[1] as trials that do not deliver informative results, even though the investigated treatment may be effective or ineffective. An informative trial, according to experts, must meet five conditions: addressing an important question, providing meaningful evidence, being feasible, conducted scientifically, and reporting methods and results promptly.

The Clinical Trial Risk Tool was created to prevent such trials by providing features like a clinical trial budget estimator based on real-world cost data. The development of the first version of the tool was published in Gates Open Research[2]. In future, the tool could retrieve past trials with similar endpoints or inclusion/exclusion criteria to improve protocol design. It could also generate personalised feedback for different stakeholders, such as medical professionals, financial planners, and patient advocates.

Fast Data Science’s Clinical Trial Risk Tool offers a solution by allowing users to upload trial protocols, where AI analyzes the document for risk and cost factors. The tool estimates trial costs and identifies risks, helping to avoid uninformative outcomes early in the design process.

References

  1. Zarin, Deborah A., Steven N. Goodman, and Jonathan Kimmelman. “Harms from uninformative clinical trials.” Jama 322.9 (2019): 813-814, https://pubmed.ncbi.nlm.nih.gov/31343666/
  2. Wood, Thomas A., and Douglas McNair. “Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness.” Gates Open Research 7.56 (2023): 56. https://gatesopenresearch.org/articles/7-56/v1
  3. Wood, Thomas A., A Tool To Tackle The Risk Of Uninformative Trials, Clinical Leader, 2025.

Unlock Your Future in NLP!

Dive into the world of Natural Language Processing! Explore cutting-edge NLP roles that match your skills and passions.

Explore NLP Jobs

Should lawyers stop using generative AI to prepare their legal arguments?
Generative aiLegal ai

Should lawyers stop using generative AI to prepare their legal arguments?

Senior lawyers should stop using generative AI to prepare their legal arguments! Or should they? A High Court judge in the UK has told senior lawyers off for their use of ChatGPT, because it invents citations to cases and laws that don’t exist!

Drug Name Recogniser Google Sheets™ plugin updated
Ai in pharma

Drug Name Recogniser Google Sheets™ plugin updated

Drug Name Recogniser Google Sheets plugin update We have updated the Drug Name Recogniser Google Sheets™ plugin to cover molecular mass, chemical formula and SMILES strings.

Fast Data Science at Hamlyn Symposium on Medical Robotics on 27 June 2025
Ai in healthcareEvents

Fast Data Science at Hamlyn Symposium on Medical Robotics on 27 June 2025

Fast Data Science at Hamlyn Symposium event on “Healing Through Collaboration: Open-Source Software in Surgical, Biomedical and AI Technologies” Join Thomas Wood of Fast Data Science for a full-day event on “Healing Through Collaboration: Open-Source Software in Surgical, Biomedical and AI Technologies” at the Hamlyn Symposium on Medical Robotics 2025 which will take place on 27th June in London.

What we can do for you

Transform Unstructured Data into Actionable Insights

Contact us